Nano-mupirocin for injection
Goldblum Amiram, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research
CERN Ahuva, HUJI, School of Medicine - IMRIC
|
Categories |
Drug delivery, Infectious disease |
|
Development Stage |
Pre-clinical efficacy studies |
|
Patent Status |
Patent pending |
|
Market |
The invention is related to the field of antibiotic resistant bacteria (N. gonorrhoeae, MRSA, Streptococcus pneumoniae) |
Highlights
A new parenteral antibiotic nano-drug based on a safe, highly efficacious mupirocin which in its current application is used only topically.
Mupirocin, is an antibiotic with a unique mode of action, which due to its unfavourable PK and ADME properties cannot be used parentraly. We modified these properties by transforming mupirocin to a nano-drug (Nano-mupirocin) by remote loading of the drug using a unique proprietary way into pegylated nano-liposomes.
Our Innovation
Mupirocin has a unique mode of action which is not shared by any other therapeutically available antibiotics: mupirocin inhibits isoleucyl tRNA synthetase required for bacterial multiplication. Therefore, cross resistance with other antibiotics is not expected. It is active against pathogens that were determined to have a potential to pose a serious and urgent threat to public health including methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae and Neisseria gonorrhoeae.
The pharmacokinetic profile of Nano-mupirocin vs free mupirocin showed superior profile. After injection of Nano-mupirocin, mupirocin plasma levels were above its MIC 24 h after administration, while after injection of the free drug it was cleared from the circulation after 15-30 min.
We showed efficacy of Nano-mupirocin in a mouse model of necrotizing fasciitis. It was active upon
injection of a single Nano-mupirocin dose 2-3 h before the bacterial challenge as well as
1- 5 h after the bacterial challenge.
Clinical Implications:
Nano-mupirocin may be useful for the treatment of gonorrhea and for deep infections such as airway infections in CF patients, osteomyelitis, pneumonia and bacterial endocarditis.
The Opportunity
* Generating Antibiotics Incentives Now (GAIN), 2012, provides five years of protection from generics, and an accelerated FDA approval process for antibiotics against specific bacteria.
* Mupirocin is an approved drug. It may therefore be suitable for 505(b)(2) application
Contact
Shoshi Keynan, Ph.D., VP, Head of Business Development, Healthcare
+972-2-658-6683
Patent Status
Granted US 10,004,688; Europe 3142642; India 351893; Japan
